MA44381A - Format d'anticorps hétérodimères multispécifiques - Google Patents

Format d'anticorps hétérodimères multispécifiques

Info

Publication number: MA44381A
Authority: MA; Morocco
Prior art keywords: antibody format; heterodimeric antibody; multispecific heterodimeric; multispecific; format
Prior art date: 2015-06-15

Application number

MA044381A

Other languages

English (en)

Inventor

Sebastian Meyer

David Urech

Original Assignee

Numab Innovation Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-15

Filing date

2016-06-15

Publication date

2019-01-23

2016-06-15 Application filed by Numab Innovation Ag filed Critical Numab Innovation Ag

2019-01-23 Publication of MA44381A publication Critical patent/MA44381A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA044381A 2015-06-15 2016-06-15 Format d'anticorps hétérodimères multispécifiques MA44381A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP15001758		2015-06-15

Publications (1)

Publication Number	Publication Date
MA44381A true MA44381A (fr)	2019-01-23

Family

ID=53434175

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA044381A MA44381A (fr)	2015-06-15	2016-06-15	Format d'anticorps hétérodimères multispécifiques

Country Status (13)

Country	Link
US (2)	US11236150B2 (fr)
EP (2)	EP3307776A1 (fr)
JP (3)	JP6839101B2 (fr)
KR (2)	KR20250091329A (fr)
CN (2)	CN107922486B (fr)
AU (3)	AU2016278586B2 (fr)
CA (1)	CA2989474C (fr)
EA (1)	EA201890041A1 (fr)
HK (1)	HK1245805A1 (fr)
IL (2)	IL256314B (fr)
MA (1)	MA44381A (fr)
MX (2)	MX395604B (fr)
WO (1)	WO2016202457A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20250091329A (ko) *	2015-06-15	2025-06-20	누맙 세러퓨틱스 아게	이종 이량체 다중 특이적 항체 포맷
EP3156417A1 (fr) *	2015-10-13	2017-04-19	Affimed GmbH	Anticorps fv multivalents
CN110709418B (zh)	2017-06-05	2023-09-26	努玛治疗有限公司	新型抗hsa抗体
WO2018224439A1 (fr)	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-hsa
WO2018224441A1 (fr)	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-cd3
US11319371B2 (en)	2017-06-05	2022-05-03	Numab Therapeutics AG	Anti-CD3 antibodies
US12098203B2 (en)	2017-06-05	2024-09-24	Numab Therapeutics AG	Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
EP3459968A1 (fr)	2017-09-20	2019-03-27	Numab Innovation AG	Nouvelles combinaisons de structure de domaines variables d'anticorps stables
IL273578B2 (en)	2017-10-10	2026-03-01	Numab Therapeutics AG	Antibodies directed against PD-1 and methods of use thereof
EP3470429A1 (fr)	2017-10-10	2019-04-17	Numab Innovation AG	Anticorps dirigés contre pdl1 et leurs procédés d'utilisation
EP3470426A1 (fr)	2017-10-10	2019-04-17	Numab Therapeutics AG	Anticorps multi-spécifique
US12202911B2 (en)	2017-10-10	2025-01-21	Numab Therapeutics AG	Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
CN111183159B (zh)	2017-10-10	2024-09-03	努玛治疗有限公司	靶向cd137的抗体及其使用方法
EP3470428A1 (fr)	2017-10-10	2019-04-17	Numab Innovation AG	Anticorps dirigés contre cd137 et leurs procédés d'utilisation
WO2019136405A1 (fr) *	2018-01-05	2019-07-11	City Of Hope	Liants de ligands multi-spécifiques
TWI839395B (zh)	2018-10-09	2024-04-21	瑞士商Ｎｕｍａｂ治療公司	靶向cd137的抗體及其使用方法
EP3636320A1 (fr)	2018-10-09	2020-04-15	Numab Therapeutics AG	Anticorps dirigés contre cd137 et leurs procédés d'utilisation
JP7525499B2 (ja)	2019-01-31	2024-07-30	ヌマブセラピューティクスアクチェンゲゼルシャフト	ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
EP3689907A1 (fr)	2019-01-31	2020-08-05	Numab Therapeutics AG	Anticorps dirigés contre il-17a et leurs procédés d'utilisation
EP3816185A1 (fr)	2019-11-04	2021-05-05	Numab Therapeutics AG	Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
EP3915580A1 (fr)	2020-05-29	2021-12-01	Numab Therapeutics AG	Anticorps multi-spécifique
WO2022002038A1 (fr) *	2020-06-30	2022-01-06	和铂医药(上海)有限责任公司	Protéine de liaison multi-spécifique d'un recruteur de cellules immunitaires, préparation et utilisation associées
WO2022002036A1 (fr) *	2020-06-30	2022-01-06	和铂医药(上海)有限责任公司	Anticorps bispécifique et son utilisation
EP3988568A1 (fr)	2020-10-21	2022-04-27	Numab Therapeutics AG	Traitement combiné
EP4019546A1 (fr)	2020-12-23	2022-06-29	Numab Therapeutics AG	Domaines variables d'anticorps qui se lient à il-31
EP4019090A1 (fr)	2020-12-23	2022-06-29	Numab Therapeutics AG	Domaines variables d'anticorps liant il-4r
EP4267614A1 (fr)	2020-12-23	2023-11-01	Numab Therapeutics AG	Domaines variables d'anticorps se liant à il-31
WO2022136693A1 (fr)	2020-12-23	2022-06-30	Numab Therapeutics AG	Domaines variables d'anticorps et anticorps ayant une immunogénicité réduite
JP7858665B2 (ja) *	2021-02-02	2026-05-14	ヌマブセラピューティックスアーゲー	Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
CN115536749A (zh)	2021-06-29	2022-12-30	三生国健药业（上海）股份有限公司	三特异性抗体、其制备方法和用途
EP4183800A1 (fr)	2021-11-19	2023-05-24	Medizinische Hochschule Hannover	Nouveaux anticorps neutralisants du sars-cov-2
CN119487062A (zh)	2022-05-06	2025-02-18	努玛治疗有限公司	具有降低的免疫原性的抗体可变结构域和抗体
EP4273162A1 (fr)	2022-05-06	2023-11-08	Numab Therapeutics AG	Domaines variables d'anticorps et anticorps présentant une immunogénicité réduite
WO2024038095A1 (fr)	2022-08-16	2024-02-22	Iome Bio	Nouveaux anticorps anti-rgmb
PE20260551A1 (es)	2023-05-19	2026-03-04	Numab Therapeutics AG	Dominios variables de anticuerpos y anticuerpos con inmunogenicidad disminuida

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001270609A1 (en) *	2000-06-30	2002-01-14	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Heterodimeric fusion proteins
ATE346866T1 (de)	2001-09-14	2006-12-15	Affimed Therapeutics Ag	Multimerische, einzelkettige, tandem-fv- antikörper
US20050003403A1 (en) *	2003-04-22	2005-01-06	Rossi Edmund A.	Polyvalent protein complex
WO2010132872A1 (fr) *	2009-05-15	2010-11-18	Novimmune S.A	Polythérapies et méthodes utilisant des agents de modulation anti-cd3 et des antagonistes anti-tnf
TWI507525B (zh)	2009-06-26	2015-11-11	Regeneron Pharma	具天然免疫球蛋白形式之易分離的雙專一性抗體
GB201000467D0 (en) *	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
US20120195900A1 (en)	2010-12-22	2012-08-02	Abbott Laboratories	Tri-variable domain binding proteins and uses thereof
TWI622597B (zh)	2011-03-28	2018-05-01	賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20150045540A1 (en) *	2011-06-28	2015-02-12	Sea Lane Biotechnologies, Llc	Multispecific stacked variable domain binding proteins
US20150203591A1 (en) *	2012-08-02	2015-07-23	Regeneron Pharmaceuticals, Inc.	Mutivalent antigen-binding proteins
SI2953977T1 (en) *	2013-02-05	2018-02-28	Sanofi	An immuno-contrast agent for use in antibody-drug conjugate therapy
JP6618463B2 (ja) *	2013-05-07	2019-12-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	三量体型抗原結合分子
CA2911946A1 (fr) *	2013-05-10	2014-11-13	Numab Ag	Constructions bispecifiques et leur utilisation dans le traitement de plusieurs maladies
HK1218549A1 (zh)	2013-06-26	2017-02-24	Numab Therapeutics AG	新型抗体框架
GB2518221A (en) *	2013-09-16	2015-03-18	Sergej Michailovic Kiprijanov	Tetravalent antigen-binding protein molecule
EP2930188A1 (fr)	2014-04-13	2015-10-14	Affimed Therapeutics AG	Molécule de liaison à l'antigène trifonctionnel
KR20250091329A (ko) *	2015-06-15	2025-06-20	누맙 세러퓨틱스 아게	이종 이량체 다중 특이적 항체 포맷
EP3156417A1 (fr)	2015-10-13	2017-04-19	Affimed GmbH	Anticorps fv multivalents

2016
- 2016-06-15 KR KR1020257019761A patent/KR20250091329A/ko active Pending
- 2016-06-15 EP EP16736380.3A patent/EP3307776A1/fr not_active Withdrawn
- 2016-06-15 CN CN201680048188.4A patent/CN107922486B/zh active Active
- 2016-06-15 EP EP22160481.2A patent/EP4047020A1/fr active Pending
- 2016-06-15 JP JP2017564881A patent/JP6839101B2/ja active Active
- 2016-06-15 AU AU2016278586A patent/AU2016278586B2/en active Active
- 2016-06-15 US US15/736,747 patent/US11236150B2/en active Active
- 2016-06-15 KR KR1020187001156A patent/KR20180012860A/ko not_active Ceased
- 2016-06-15 MA MA044381A patent/MA44381A/fr unknown
- 2016-06-15 CA CA2989474A patent/CA2989474C/fr active Active
- 2016-06-15 MX MX2017016188A patent/MX395604B/es unknown
- 2016-06-15 CN CN202210532747.6A patent/CN115057936B/zh active Active
- 2016-06-15 HK HK18105091.7A patent/HK1245805A1/zh unknown
- 2016-06-15 WO PCT/EP2016/001002 patent/WO2016202457A1/fr not_active Ceased
- 2016-06-15 EA EA201890041A patent/EA201890041A1/ru unknown
2017
- 2017-12-13 MX MX2022011472A patent/MX2022011472A/es unknown
- 2017-12-14 IL IL256314A patent/IL256314B/en unknown
2021
- 2021-02-12 JP JP2021021147A patent/JP7140861B2/ja active Active
2022
- 2022-01-29 US US17/588,262 patent/US11879005B2/en active Active
- 2022-05-29 IL IL293435A patent/IL293435B2/en unknown
- 2022-08-18 AU AU2022218544A patent/AU2022218544B2/en active Active
- 2022-09-08 JP JP2022142827A patent/JP7457764B2/ja active Active
2025
- 2025-09-29 AU AU2025238141A patent/AU2025238141A1/en active Pending

Also Published As

Publication number	Publication date
MX2017016188A (es)	2018-07-06
US20220332797A1 (en)	2022-10-20
CN107922486A (zh)	2018-04-17
AU2025238141A1 (en)	2025-10-23
IL293435B2 (en)	2026-08-01
IL256314A (en)	2018-02-28
EP3307776A1 (fr)	2018-04-18
WO2016202457A8 (fr)	2017-11-30
EP4047020A1 (fr)	2022-08-24
CA2989474A1 (fr)	2016-12-22
MX395604B (es)	2025-03-25
AU2016278586A1 (en)	2018-01-04
AU2022218544A1 (en)	2022-09-15
WO2016202457A1 (fr)	2016-12-22
CN107922486B (zh)	2022-05-31
AU2016278586B2 (en)	2022-05-19
NZ738221A (en)	2024-10-25
CN115057936B (zh)	2025-05-30
JP2022177097A (ja)	2022-11-30
MX2022011472A (es)	2023-03-01
EA201890041A1 (ru)	2018-07-31
JP7457764B2 (ja)	2024-03-28
US11879005B2 (en)	2024-01-23
US11236150B2 (en)	2022-02-01
IL256314B (en)	2022-06-01
JP6839101B2 (ja)	2021-03-03
US20180355024A1 (en)	2018-12-13
HK1245805A1 (zh)	2018-08-31
KR20250091329A (ko)	2025-06-20
CA2989474C (fr)	2023-09-05
JP2018522545A (ja)	2018-08-16
IL293435A (en)	2022-07-01
JP2021087436A (ja)	2021-06-10
JP7140861B2 (ja)	2022-09-21
AU2022218544B2 (en)	2025-09-11
IL293435B1 (en)	2026-04-01
KR20180012860A (ko)	2018-02-06
CN115057936A (zh)	2022-09-16

Publication	Publication Date	Title
EP3359573A4 (fr)	2019-05-29	Marquage d'anticorps
EP3498840A4 (fr)	2020-05-06	Anticorps anti-lag-3
MA50352A (fr)	2020-08-19	Anticorps multispécifiques
EP3423089A4 (fr)	2019-10-23	Anticorps anti-tigit
EP3334757A4 (fr)	2019-04-03	Anticorps anti-tigit
MA49034A (fr)	2020-02-12	Anticorps anti-lag3
EP3297671A4 (fr)	2019-02-06	Anticorps anti-ror1
EP3589313A4 (fr)	2021-05-19	Anticorps anti-tigit
MA45004A (fr)	2019-03-27	Anticorps spécifiques anti-wt1-hla
MA47268A (fr)	2019-11-20	Anticorps anti-gpc3
MA44054A (fr)	2018-10-24	Plateforme d'anticorps bispécifique
EP3684806A4 (fr)	2021-09-22	Nouveaux anticorps anti-cd3epsilon
EP3507307A4 (fr)	2020-04-22	Anticorps bispécifiques
EP3334763A4 (fr)	2019-04-03	Nouveaux anticorps anti-pd-1
MA47472A (fr)	2019-12-18	Anticorps
MA44236A (fr)	2018-12-26	Anticorps anti-tgfbêta 2
EP3492591A4 (fr)	2020-04-01	Anticorps anti-b7-h4
EP3526247A4 (fr)	2021-04-14	Anticorps anti-il1-rap
EP2968553A4 (fr)	2016-10-19	Formulations d'anticorps
EP3399992A4 (fr)	2019-07-31	Anticorps autoréticulants
EP3484919A4 (fr)	2020-03-04	Anticorps anti-bêta-amyloïde
MA51554A (fr)	2020-11-18	Anticorps il-6 améliorés
EP3617231A4 (fr)	2021-04-07	Anticorps anti-gpc-1
EP3349794A4 (fr)	2019-07-31	Anticorps anti-cd115
EP3596126A4 (fr)	2021-03-03	Nouveaux anticorps anti-trkb